Last updated: February 23, 2026
What is the drug associated with NDC 51407-0443?
NDC 51407-0443 corresponds to Xywav (calcium, magnesium, sodium, and potassium oxybates oral solution). Approved by the FDA in July 2020, Xywav is used to treat narcolepsy and cataplexy in adult patients.
Market Size and Adoption Trends
The following data outlines the current market dynamics:
- Market Size (2023): Estimated US sales of approximately $600 million.
- Patient Population: Approximately 80,000 patients in the U.S. diagnosed with narcolepsy, with about 20,000 actively on treatment.
- Market Penetration: Xywav has secured an estimated 70% share among oxybate therapies.
Competitive Landscape
Xywav's main competitors are:
- Sodium Oxybate (Xyrem): First-in-class oxybate therapy, launched in 2002.
- Other Wakefulness Agents: Modafinil, armodafinil, and pitolisant.
Market Share Distribution (2023):
| Product |
Market Share |
Estimated Sales (USD million) |
| Xywav |
65% |
390 |
| Xyrem |
30% |
180 |
| Others |
5% |
30 |
Xywav's lower dosing frequency and better tolerability have driven increased adoption.
Pricing Analysis and Projections
Current Pricing
- Average Wholesale Price (AWP): Approx. $14 per ml.
- Average Per-Patient Annual Cost: ~$90,000, varying with dosage and treatment duration.
Price Trends (2020–2023)
- The launch price was approximately $13.50 per ml.
- Prices increased modestly (~2% annually) due to inflation and formulary negotiations.
- Pharmaco-economic considerations support stable or slightly rising prices as generic competition is absent.
Price Projections: 2024-2028
| Year |
Estimated Price Per mL |
Assumptions |
| 2024 |
$14.50 |
Inflation-adjusted; negligible generic entry |
| 2025 |
$15.00 |
Continued inflation and demand stability |
| 2026 |
$15.50 |
Price plateau expected if no new entrants |
| 2027 |
$16.00 |
Possible price increase for premium services |
| 2028 |
$16.50 |
Market maturity, limited downward pressure |
Revenue Projection
Taking into account estimated patient numbers, the revenue from Xywav could grow from approximately $390 million in 2023 to around $520 million in 2028, assuming steady market share and pricing.
Regulatory and Policy Impact
- Patent Protection: Patents on Xywav extend until 2030, limiting generic competition.
- Reimbursement Trends: Payers are increasingly negotiating formulary placements, constraining net prices.
- Off-label Use: Limited off-label indications reduce market expansion risks.
Key Risks
- Generic Entry: Expected post-2030, which could put downward pressure on prices.
- Market Saturation: Plateauing treatment penetration could limit revenue growth.
- Pricing Pressure: Payer negotiations or policy changes could impact list prices.
Conclusions
The Xywav market remains stable with steady demand in narcolepsy treatment. Pricing is likely to increase modestly through 2028, influenced by inflation, patient growth, and market maturity. Competition from existing oxybates and generics will define pricing dynamics post-2030.
Key Takeaways
- The drug's current market value exceeds $600 million annually.
- Price per mL is projected to increase approximately 3.5% annually.
- Revenue growth hinges on sustained market penetration and minimal pricing concessions.
- Patent protections shield the drug from generic competition until 2030.
- Competitive landscape favors Xywav due to dosing and tolerability advantages.
FAQs
1. When is generic oxybate expected to enter the market?
Generic oxybate is expected after patent expiry around 2030, subject to patent challenges and regulatory approvals.
2. How does Xywav compare to Xyrem in pricing?
Xywav generally costs slightly more per milliliter than Xyrem due to formulation and dosing convenience, but the annual treatment costs are comparable given market share differences.
3. What are the key factors influencing price stability?
Limited competition until 2030, positive reimbursement trends, and demand stability bolster pricing.
4. How might policy changes affect Xywav’s market share?
Payer negotiations, formulary policies, or new therapies could reduce market share and exert price pressure.
5. What is the potential for market expansion?
New indications or expanded use in other sleep-related disorders could drive growth, but current data limits projections to narcolepsy treatment.
Sources
[1] FDA. (2020). Xywav Approval Letter. Retrieved from https://www.fda.gov
[2] IQVIA. (2023). US Prescription Data.
[3] EvaluatePharma. (2023). Market Forecasts for Narcolepsy Treatments.
